Results 171 to 180 of about 7,093,683 (260)

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

Predictors for Home Discharge and Need for Medical Care at Home in Paediatric ICU Patients: A Single-Centre Retrospective Study. [PDF]

Nurs Crit Care
Oyagi M, Bamba S, Takashima K, Imashuku Y, Ryuno H, Shiomi N, Kitagawa H, Hitosugi M.   +7 more
europepmc   +1 more source

Revisiting Mission‐Oriented Cancer Research to tackle the increasing burden of cancer in Europe–a policy perspective

Molecular Oncology, EarlyView.
Translational cancer research and its implementation through competitively selected Comprehensive Cancer Centers across Europe should be the primary policy focus for addressing the increasing cancer burden in Europe and counteract the present main strategy to convert cancer to a chronic disease.
Manuel Heitor, Julio Celis, Ulrik Ringborg   +2 more
wiley   +1 more source

Willingness of Older Adults to Travel for Medical Care.

JAMA Netw Open
Burke J, Ozawa T, Liu Y, Ye W, Mattke S.
europepmc   +1 more source

Awareness of Emergency Medical Care Among School Teachers in Rabigh City. [PDF]

Cureus
Alharbi HAA, Almutairi MM, Alharbi FS, Al Harbi AM, Almuthaybiri MM, Alharbi BA, Almoteri KH, Alharbi SA, Almotari SA, Alharbi AM, Almuthaybiri SM.   +10 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Multiple Chronic Conditions, Delayed Medical Care and Hospitalization: A Comparison Between the United States and Taiwan. [PDF]

Int J Health Policy Manag
Wang CY, Claire Lin CC, Kuo RN, Liao JM.
europepmc   +1 more source

Checkpoint blockade and the stem‐like T cell trade‐off

Molecular Oncology, EarlyView.
Stem‐like T cells are key to the success of programmed cell death protein 1 (PD1) blockade, as they sustain long‐term anti‐tumor response by continuously generating effector CD8+ T cells. However, how these cells are maintained in cancer is not fully understood. Hor et al.
Julie M. Mazet, Johanna A. Joyce
wiley   +1 more source

How the hybrid rules of free and paid medical care affect the post-socialist health system. [PDF]

BMC Health Serv Res
Shishkin S, Sheiman I, Potapchik E, Sazhina S, Vlassov V.   +4 more
europepmc   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source